1. Kaser, A, Zeissig, S, Blumberg, RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573–621.
Google Scholar | Crossref | Medline | ISI2. Singh, S, Dulai, PS, Zarrinpar, A, et al. Obesity in IBD: Epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol 2017; 14: 110–121.
Google Scholar | Crossref | Medline3. Ng, M, Fleming, T, Robinson, M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766–781.
Google Scholar | Crossref | Medline | ISI4. Afshin, A, Forouzanfar, MH, Reitsma, MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13–27.
Google Scholar | Crossref | Medline5. Molodecky, NA, Soon, IS, Rabi, DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.e42; quiz e30.
Google Scholar | Crossref | Medline | ISI6. Kaplan, GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12: 720–727.
Google Scholar | Crossref | Medline7. Ng, SC, Zeng, Z, Niewiadomski, O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study From 8 countries in Asia and Australia. Gastroenterology 2016; 150: 86–95.e83; quiz e13–e84.
Google Scholar | Crossref | Medline | ISI8. Blain, A, Cattan, S, Beaugerie, L, et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002; 21: 51–57.
Google Scholar | Crossref | Medline9. Moran, GW, Dubeau, MF, Kaplan, GG, et al. The increasing weight of Crohn's disease subjects in clinical trials: A hypothesis-generating time-trend analysis. Inflamm Bowel Dis 2013; 19: 2949–2956.
Google Scholar | Crossref | Medline10. Khalili, H, Ananthakrishnan, AN, Konijeti, GG, et al. Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2015; 21: 361–368.
Google Scholar | Crossref | Medline11. Qin, B, Yang, M, Fu, H, et al. Body mass index and the risk of rheumatoid arthritis: A systematic review and dose-response meta-analysis. Arthritis Res Ther 2015; 17: 86.
Google Scholar | Crossref | Medline12. Sterry, W, Strober, BE, Menter, A, et al. Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649–655.
Google Scholar | Crossref | Medline | ISI13. Peyrin-Biroulet, L, Gonzalez, F, Dubuquoy, L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61: 78–85.
Google Scholar | Crossref | Medline | ISI14. Iannone, F, Lopalco, G, Rigante, D, et al. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev 2016; 15: 447–450.
Google Scholar | Crossref | Medline15. Versini, M, Jeandel, PY, Rosenthal, E, et al. Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev 2014; 13: 981–1000.
Google Scholar | Crossref | Medline | ISI16. Singh, S, Facciorusso, A, Singh, AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018; 13: e0195123.
Google Scholar | Crossref | Medline17. Pringle, PL, Stewart, KO, Peloquin, JM, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn's disease. Inflamm Bowel Dis 2015; 21: 2304–2310.
Google Scholar | Medline18. Stabroth-Akil, D, Leifeld, L, Pfützer, R, et al. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis 2015; 30: 237–242.
Google Scholar | Crossref | Medline19. Braga Neto, MB, Gregory, M, Ramos, GP, et al. De-novo inflammatory bowel disease after bariatric surgery: A large case series. J Crohns Colitis 2018; 12: 452–457.
Google Scholar | Crossref | Medline20. Gomollón, F, Dignass, A, Annese, V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25.
Google Scholar | Crossref | Medline21. Magro, F, Gionchetti, P, Eliakim, R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
Google Scholar | Crossref | Medline22. Pittet, V, Michetti, P, Mueller, C, et al. Cohort profile update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2019; 48: 385–386f.
Google Scholar | Crossref | Medline23. Best, WR, Becktel, JM, Singleton, JW, et al. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–444.
Google Scholar | Crossref | Medline | ISI24. Truelove, SC, Witts, LJ. Cortisone in ulcerative colitis: Preliminary report on a therapeutic trial. Br Med J 1954; 2: 375–378.
Google Scholar | Crossref | Medline25. Truelove, SC, Witts, LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1955; 2: 1041–1048.
Google Scholar | Crossref | Medline26. Silverberg, MS, Satsangi, J, Ahmad, T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5A–36A.
Google Scholar | Crossref | Medline27. Guyatt, G, Mitchell, A, Irvine, EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804–810.
Google Scholar | Crossref | Medline | ISI28. Ware, JE, Sherbourne, CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
Google Scholar | Crossref | Medline | ISI29. Flores, A, Burstein, E, Cipher, DJ, et al. Obesity in inflammatory bowel disease: A marker of less severe disease. Dig Dis Sci 2015; 60: 2436–2445.
Google Scholar | Crossref | Medline30. Mendall, MA, Gunasekera, AV, John, BJ, et al. Is obesity a risk factor for Crohn's disease? Dig Dis Sci 2011; 56: 837–844.
Google Scholar | Crossref | Medline31. Nic Suibhne, T, Raftery, TC, McMahon, O, et al. High prevalence of overweight and obesity in adults with Crohn's disease: Associations with disease and lifestyle factors. J Crohns Colitis 2013; 7: e241–e248.
Google Scholar | Crossref | Medline32. Jain, A, Nguyen, NH, Proudfoot, JA, et al. Impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol 2019; 114: 630–639.
Google Scholar | Crossref | Medline33. Reenaers, C, Bossuyt, P, Hindryckx, P, et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018; 6: 1117–1125.
Google Scholar | SAGE Journals | ISI34. Ballou, S, Singh, P, Rangan, V, et al. Obesity is associated with significantly increased risk for diarrhoea after controlling for demographic, dietary and medical factors: A cross-sectional analysis of the 2009–2010 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2019; 50: 1019–1024.
Google Scholar | Crossref | Medline35. Sadik, R, Abrahamsson, H, Ung, KA, et al. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004; 99: 711–718.
Google Scholar | Crossref | Medline36. Delgado-Aros, S, Camilleri, M, Garcia, MA, et al. High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol 2008; 295: G382–G388.
Google Scholar | Crossref | Medline37. Rajilić-Stojanović, M, Biagi, E, Heilig, HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792–1801.
Google Scholar | Crossref | Medline | ISI38. Pavelock, N, Masood, U, Minchenberg, S, et al. Effects of obesity on the course of inflammatory bowel disease. Proc (Bayl Univ Med Cent) 2019; 32: 14–17.
Google Scholar | Crossref | Medline39. Seminerio, JL, Koutroubakis, IE, Ramos-Rivers, C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis 2015; 21: 2857–2863.
Google Scholar | Crossref | Medline40. Hass, DJ, Brensinger, CM, Lewis, JD, et al. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 482–488.
Google Scholar | Crossref | Medline | ISI41. Dotan, I, Ron, Y, Yanai, H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study. Inflamm Bowel Dis 2014; 20: 2247–2259.
Google Scholar | Crossref | Medline | ISI